ES2615169T3 - Composiciones y procedimientos de activación de la inmunidad innata y alérgica - Google Patents

Composiciones y procedimientos de activación de la inmunidad innata y alérgica Download PDF

Info

Publication number
ES2615169T3
ES2615169T3 ES10001123.8T ES10001123T ES2615169T3 ES 2615169 T3 ES2615169 T3 ES 2615169T3 ES 10001123 T ES10001123 T ES 10001123T ES 2615169 T3 ES2615169 T3 ES 2615169T3
Authority
ES
Spain
Prior art keywords
protollin
antigen
mice
lps
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES10001123.8T
Other languages
English (en)
Spanish (es)
Inventor
George H. Lowell
David S. Burt
David H. Jones
Joseph J. Zimmermann
Clement Rioux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ID Biomedical Corp of Quebec
Original Assignee
ID Biomedical Corp of Quebec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ID Biomedical Corp of Quebec filed Critical ID Biomedical Corp of Quebec
Application granted granted Critical
Publication of ES2615169T3 publication Critical patent/ES2615169T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ES10001123.8T 2003-10-22 2004-10-22 Composiciones y procedimientos de activación de la inmunidad innata y alérgica Expired - Lifetime ES2615169T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US51361403P 2003-10-22 2003-10-22
US513614P 2003-10-22
US55984204P 2004-04-06 2004-04-06
US559842P 2004-04-06

Publications (1)

Publication Number Publication Date
ES2615169T3 true ES2615169T3 (es) 2017-06-05

Family

ID=34555907

Family Applications (2)

Application Number Title Priority Date Filing Date
ES10001123.8T Expired - Lifetime ES2615169T3 (es) 2003-10-22 2004-10-22 Composiciones y procedimientos de activación de la inmunidad innata y alérgica
ES04796097T Expired - Lifetime ES2346441T3 (es) 2003-10-22 2004-10-22 Composiciones y procedimientos para activar una inmunidad innata y alergica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES04796097T Expired - Lifetime ES2346441T3 (es) 2003-10-22 2004-10-22 Composiciones y procedimientos para activar una inmunidad innata y alergica.

Country Status (8)

Country Link
US (4) US8173140B2 (https=)
EP (2) EP1689433B1 (https=)
JP (2) JP4966661B2 (https=)
AT (1) ATE472336T1 (https=)
CA (1) CA2543080C (https=)
DE (1) DE602004027940D1 (https=)
ES (2) ES2615169T3 (https=)
WO (1) WO2005042017A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7524509B2 (en) * 2001-03-09 2009-04-28 Id Biomedical Corporation Of Quebec Proteosome-liposaccharide vaccine adjuvant
US7255867B2 (en) 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
WO2005042017A1 (en) * 2003-10-22 2005-05-12 Id Biomedical Corporation Of Quebec Compositions and methods for activating innate and allergic immunity
CN101039691B (zh) * 2004-06-25 2013-07-31 魁北克益得生物医学公司 用于治疗神经疾病的组合物和方法
CN103800906B (zh) 2009-03-25 2017-09-22 德克萨斯大学系统董事会 用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物
WO2011106525A2 (en) 2010-02-26 2011-09-01 The Brigham And Women's Hospital, Inc. Methods of treating cerebral amyloid angiopathy
US20140154288A1 (en) 2011-05-13 2014-06-05 Folia Biotech Inc. Papaya mosaic virus compositions and uses thereof for stimulation of the innate immune response
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
BR112021018086A2 (pt) * 2019-03-14 2021-11-23 Univ Arizona Método de tratamento e/ou prevenção de asma, exacerbações de asma, asma alérgica e/ou condições associadas com microbiota relacionadas a distúrbios respiratórios
WO2021222354A2 (en) * 2020-04-28 2021-11-04 Nova Southeastern University Compositions including alamandine peptides and methods for treatment of pulmonary disease using alamandine peptides
CA3208643A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707543A (en) 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US5726292A (en) 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
DE69625802T2 (de) * 1995-03-13 2003-11-13 The Secretary Of State For Defence, Salisbury Impfstoffe gegen die pest
CN1211192A (zh) 1995-09-18 1999-03-17 美国陆军医疗材料研究指挥部 生产非共价复合的多价蛋白体亚基疫苗的改进方法
CA2400468C (en) 2000-02-15 2012-12-18 Intellivax International Inc. Proteosome influenza vaccine
CN1549726A (zh) * 2000-07-31 2004-11-24 耶鲁大学 先天性免疫系统指导的疫苗
US7524509B2 (en) * 2001-03-09 2009-04-28 Id Biomedical Corporation Of Quebec Proteosome-liposaccharide vaccine adjuvant
EP1379552B2 (en) * 2001-04-20 2014-11-19 The Institute for Systems Biology Toll-like receptor 5 ligands and methods of use
US8703146B2 (en) * 2001-04-20 2014-04-22 Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
WO2002100340A2 (en) * 2001-06-08 2002-12-19 Avant Immunotherapeutics, Inc. Improved vaccination against anthrax
US20030026780A1 (en) * 2001-07-18 2003-02-06 Hood Leroy E. Innate immunity mediated methods of treating pathological conditions
CA2524485A1 (en) * 2003-05-05 2004-11-18 Id Biomedical Corporation Of Quebec Vaccinating against infectious diseases using proteosomes
US7368537B2 (en) 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
US20050152919A1 (en) * 2003-09-15 2005-07-14 Id Biomedical Corporation Of Quebec Measles subunit vaccine
WO2005042017A1 (en) 2003-10-22 2005-05-12 Id Biomedical Corporation Of Quebec Compositions and methods for activating innate and allergic immunity
CN101039691B (zh) * 2004-06-25 2013-07-31 魁北克益得生物医学公司 用于治疗神经疾病的组合物和方法
EP1778283A2 (en) 2004-06-30 2007-05-02 ID Biomedical Corporation of Quebec Vaccine compositions for treating coronavirus infection
EP2274320A1 (en) * 2008-04-25 2011-01-19 ID Biomedical Corporation of Quebec Methods for preparing immunogenic compositions

Also Published As

Publication number Publication date
EP2174665B1 (en) 2016-11-16
US20140234374A1 (en) 2014-08-21
EP2174665A3 (en) 2010-06-23
JP4966661B2 (ja) 2012-07-04
ES2346441T3 (es) 2010-10-15
US9433672B2 (en) 2016-09-06
EP1689433A1 (en) 2006-08-16
ATE472336T1 (de) 2010-07-15
DE602004027940D1 (de) 2010-08-12
EP2174665A2 (en) 2010-04-14
US20120276140A1 (en) 2012-11-01
CA2543080A1 (en) 2005-05-12
JP2011157380A (ja) 2011-08-18
US8173140B2 (en) 2012-05-08
EP1689433B1 (en) 2010-06-30
US20090324639A1 (en) 2009-12-31
WO2005042017A1 (en) 2005-05-12
US20090318337A1 (en) 2009-12-24
US8709447B2 (en) 2014-04-29
JP2007509166A (ja) 2007-04-12
CA2543080C (en) 2019-01-08

Similar Documents

Publication Publication Date Title
US9433672B2 (en) Compositions and methods for activating innate and allergic immunity
ES2445798T3 (es) Novedosos compuestos inmunoadyuvantes basados en flagelina y uso de los mismos
JP4137640B2 (ja) 新規プロテオソーム−リポサッカリドワクチンアジュバント
JP2012501959A (ja) Ｙｅｒｓｉｎｉａｐｅｓｔｉｓ抗原を含む組成物
KR20140043348A (ko) 리포솜 제제
JP2011190278A (ja) 粘膜体表面に接触させてワクチン抗原を包含する物質の効果を調節する新規非抗原性粘膜アジュバント処方
US20090175903A1 (en) Measles subunit vaccine
AU2007302633A1 (en) Flu vaccine admixture of mannan and flu antigen
JP2015525748A (ja) 温度に安定なワクチン製剤
US20140161836A1 (en) Carious tooth vaccine and preparation method
Gartner et al. Mucosal prime-boost vaccination for tuberculosis based on TLR triggering OprI lipoprotein from Pseudomonas aeruginosa fused to mycolyl-transferase Ag85A
US10293041B2 (en) Multivalent stable vaccine composition and methods of making same
JP2016502533A (ja) シュードモナス抗原および抗原の組み合わせ
WO2001093906A1 (fr) Composition adjuvante comprenant la proteine fha ou un fragment de la proteine fha sous forme libre
AU2004235815A1 (en) Vaccinating against infectious diseases using proteosomes
Acosta et al. TB VACCINES BASED ON PROTEOLIPOSOMES AND LIPOSOMES FROM NON PATHOGENIC MYCOBACTERIA
WO2016007797A1 (en) Multivalent stable vaccine composition and methods of making same
KR20150001075A (ko) 수지상 세포를 표적으로 하는 항체를 비강 경로로 투여하는 호흡기 점막 면역 방법 및 이를 이용한 전달 장치
HK1188467A (en) Novel immunoadjuvant flagellin-based compounds and use thereof